Overview
Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).
Status:
Terminated
Terminated
Trial end date:
2016-04-01
2016-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
BI 655064 will be administered subcutaneously once weekly in patients with immune thrombocytopenic purpura (ITP) for up to 12 weeks.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Boehringer Ingelheim
Criteria
Inclusion criteria:Male and female chronic immune ITP patients
Exclusion criteria:
Any treatment of ITP excluded except for a stable dose of corticosteroids (up to 20 mg)